Navigation Links
PharmAthene Reports Year End 2008 Financial Results

ANNAPOLIS, Md., March 30, /PRNewswire-FirstCall/ -- PharmAthene, Inc. (NYSE Amex: PIP), a biodefense company developing medical countermeasures against biological and chemical threats, today reported operational and financial results for the year ended December 31, 2008.

For the years ended December 31, 2008 and 2007, the Company reported revenues of $32.9 million and $14.6 million, respectively. Revenues for the full year 2008 consisted primarily of contract funding from the U.S. government for the development of the Company's medical countermeasures, Protexia(R), SparVax(TM) and RypVax(TM). Revenues for the year ended December 31, 2008 increased by $11.9 million as a result of the Avecia vaccines acquisition in the second quarter of 2008, and particularly the acquired U.S. government contracts supporting the development of SparVax(TM), our third generation rPA anthrax vaccine candidate, and RypVax(TM).

Research and development expenses for the years ended December 31, 2008 and 2007 were $31.8 million and $16.6 million, respectively. Expenses in 2008 resulted from research and development activities related to programs for Valortim(R) and Protexia(R) as well as from activities related to the SparVax(TM) and RypVax(TM) programs, which were acquired in the second quarter of 2008. The increase in research and development expenses in 2008 is primarily due to programs acquired as a result of the Avecia acquisition, as well as process development, manufacturing and increased clinical activities during the year, partially offset by reduced internal resource costs.

General and administrative expenses for the years ended December 31, 2008 and 2007 were $19.4 million and $13.9 million, respectively. General and administrative expenses increased as a result of additional employee costs due to the increase in headcount following the Avecia acquisition, as well as increased travel expenses, non-cash stock compensation expense, and legal and consulting expenses.

For the year ended December 31, 2008, the Company's net loss attributable to common shareholders was $36.4 million or $1.59 per share, compared to net loss attributable to common shareholders of $17.7 million or $1.88 per share in the same period of 2007.

As of December 31, 2008, available cash, cash equivalents and short term investments totaled $22.9 million, excluding restricted cash totaling $13.3 million. In addition, on March 27, 2009, the Company closed on the public sale of an aggregate of 2,116,055 newly issued shares of its common stock at $2.60 per share and warrants to purchase an aggregate of 705,354 shares of its common stock at an exercise price of $3.00 per share, resulting in aggregate gross proceeds of approximately $5.5 million.

"The past year represented an important phase in the Company's growth cycle, during which time we successfully executed on our milestones with the goal of transitioning from a product development company to one emphasizing procurement and delivery of next-generation medical countermeasures to the Strategic National Stockpile," said David P. Wright, President and Chief Executive Officer of PharmAthene.

"Our acquisition of Avecia's biodefense vaccines portfolio, completed in April 2008, created an expanded product portfolio that now includes five potential best-in-class, next generation product candidates, and important critical mass - particularly with respect to our anthrax franchise," continued Mr. Wright.

"We anticipate achieving important milestones in 2009 in each of these programs. We expect our on-going Phase I clinical trial of Protexia(R) to be completed this year. In addition, we also expect to commence a Phase I clinical trial of Valortim(R) in combination with antibiotics. Notably, we should also hear whether SparVax(TM), our novel second generation recombinant protective antigen vaccine candidate, has been selected by the Biomedical Advanced Research and Development Authority (BARDA) to receive an advanced development and procurement contract," said Mr. Wright. In 2008 the Department of Health and Human Services issued a formal solicitation, to which PharmAthene responded, requesting advanced development and procurement of 25 million doses of a recombinant protective antigen vaccine for the Strategic National Stockpile.

Conference Call and Webcast Information

PharmAthene management will host a conference call to discuss the Company's 2008 year-end results on March 30, 2009, at 4:30 p.m., E.T. The dial-in number for U.S. callers is 1-866-383-8003 and for international callers is 617-597-5330. The participant passcode is 25699583.

A replay of the conference call will be available for 30 days, beginning at approximately 7:30 p.m. E.T. on March 30, 2009 until approximately 11:59 p.m. E.T. April 30, 2009. The dial-in number for U.S. callers is 1-888-286-8010, and for international callers is 617-801-6888. The participant passcode is 35301584.

The webcast of the conference call can be accessed from the company's website at A link to the webcast may be found on the Investor Relations section of the website.

About PharmAthene, Inc.

PharmAthene was formed to meet the critical needs of the United States and its allies by developing and commercializing medical countermeasures against biological and chemical weapons. PharmAthene's lead product development programs include:

  • SparVax(TM) - a second generation recombinant protective antigen (rPA) anthrax vaccine
  • Valortim(R) - a fully human monoclonal antibody for the prevention and treatment of anthrax infection
  • Protexia(R) - a novel bioscavenger for the prevention and treatment of morbidity and mortality associated with exposure to chemical nerve agents
  • RypVax(TM) - a recombinant dual antigen vaccine for plague
  • A third generation rPA anthrax vaccine.

For more information about PharmAthene, please visit

Statement on Cautionary Factors

Except for the historical information presented herein, matters discussed may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Statements that are not historical facts, including statements preceded by, followed by, or that include the words "potential"; "believe"; "anticipate"; "intend"; "plan"; "expect"; "estimate"; "could"; "may"; "should"; or similar statements are forward-looking statements. PharmAthene disclaims, however, any intent or obligation to update these forward-looking statements. Risks and uncertainties include risk associated with the reliability of the results of the studies relating to human safety and possible adverse effects resulting from the administration of the Company's product candidates, unexpected funding delays and/or reductions or elimination of U.S. government funding for one or more of the Company's development programs, including without limitation our bid related to SparVax(TM) under the Department of Health and Human Services Request for Proposals for an Anthrax Recombinant Protective Antigen (rPA) Vaccine for the Strategic National Stockpile, the award of government contracts to our competitors, unforeseen safety issues, challenges related to the development, scale-up, and/or process validation of manufacturing processes for our product candidates, unexpected determinations that these product candidates prove not to be effective and/or capable of being marketed as products, as well as risks detailed from time to time in PharmAthene's Forms 10-K and 10-Q under the caption "Risk Factors" and in its other reports filed with the U.S. Securities and Exchange Commission (the "SEC").

Copies of PharmAthene's public disclosure filings are available from its investor relations department and our website under the investor relations tab at

                                PHARMATHENE, INC.
                          CONSOLIDATED BALANCE SHEETS

                                                      December 31,
                                                  2008           2007

    Current assets:
        Cash and cash equivalents           $19,752,404    $40,582,643
        Restricted Cash                      12,000,000              -
        Short-term investments                3,190,912     12,153,945
        Accounts receivable                   8,890,077      4,005,694
        Other receivables                     1,391,512      1,240,069
        Prepaid expenses and other
         current assets                         917,125        492,294

    Total current assets                     46,142,030     58,474,645

    Long-term restricted cash                 1,250,000              -
    Property and equipment, net               5,313,219      6,571,024
    Patents, net                                925,489      1,312,991
    Other long term assets                      220,531        183,588
    Deferred costs                               37,092         68,884
    Goodwill                                  2,502,909              -

    Total assets                            $56,391,270    $66,611,132

    Current Liabilities:
        Accounts payable                     $3,870,871     $1,393,664
        Accrued expenses and other
         liabilities                         14,624,757      3,602,886
        Convertible notes                    13,377,505              -
        Current portion of long term debt     4,000,000      4,000,000

    Total current liabilities                35,873,133      8,996,550
    Other long term liabilities                 626,581        374,040
    Long-term debt                              928,117     16,668,458

    Total liabilities                        37,427,831     26,039,048

    Stockholders' deficit:
        Common stock, $0.0001 par value;
         100,000,000 shares authorized;
         25,890,143 and 22,087,121 shares
         issued and outstanding at December
         31, 2008 and 2007, respectively;         2,589          2,209
        Additional paid-in capital          142,392,163    126,490,647
        Accumulated other comprehensive
         income (loss)                          386,351      1,481,779
        Accumulated deficit                (123,817,664)   (87,402,551)

    Total stockholders' equity               18,963,439     40,572,084

    Total liabilities and stockholders'
     equity                                 $56,391,270    $66,611,132

                                 PHARMATHENE, INC.

                                                Year ended December 31,
                                              2008                  2007

    Contract revenue                    $32,821,526           $14,624,595
    Other revenue                            89,802                19,020

                                         32,911,328            14,643,615

    Operating expenses:
      Research and development           31,812,431            16,559,670
      General and administrative         19,397,532            13,882,023
      Acquired in-process research and
       development                       16,131,002                     -
      Depreciation and amortization         813,891               705,370

    Total operating expenses             68,154,856            31,147,063

    Loss from operations                (35,243,528)          (16,503,448)
    Other income (expense):
      Interest income                     1,225,471             1,122,565
      Gain on extinguishment of debt              -               886,963
      Other income                           58,106                     -
      Interest expense                   (2,573,406)           (2,122,624)
      Change in market value of
       derivative instruments               118,244             3,029,241

    Total other income (expense)         (1,171,585)            2,916,145

    Net loss                            (36,415,113)          (13,587,303)
    Accretion of redeemable
     convertible preferred stock to
     redemptive value                             -            (4,133,733)

    Net loss attributable to common
     shareholders                      $(36,415,113)         $(17,721,036)

    Basic and diluted net loss per
     share                                   $(1.59)               $(1.88)

    Weighted average shares used in
     calculation of basic and diluted
     net loss per share                  22,944,066             9,442,885

SOURCE PharmAthene, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. PharmAthene to Present at the Rodman and Renshaw/Acumen BioFin 9th Annual Healthcare Conference
2. PharmAthene and Medarex Announce Additional $0.8 Million U.S. Government Appropriation for Continued Development of Anthrax Therapeutic Valortim(TM)
3. New Study Reports High Injury Rates for Hotel Workers, Even Higher Rates for Women and Nonwhites
4. Haemacure Reports Third Quarter 2007 Results
5. First-Ever List of the 5,000 Fastest-Growing Businesses Reports Total Revenue of $194.5 Billion
6. Consumer Reports Analysis: Drugs for Nerve Pain, Fibromyalgia Effective, But Not Always Best
7. MDS Reports Third Quarter 2007 Results
8. Allied Healthcare Reports Strong Fourth Quarter, Flat Net Income for Fiscal 2007 vs. 2006
9. AtriCure Reports First Human Implant of the Cosgrove-Gillinov Left Atrial Appendage Occlusion System
10. NMHC Reports Fourth Quarter and Fiscal Year 2007 Financial Results
11. Blue Cross and Blue Shield of Florida Reports Eighteenth Consecutive Year of Positive Performance
Post Your Comments:
(Date:10/13/2017)... ... October 13, 2017 , ... ... Software Development, has been awarded a contract by the Center for Medicare and ... aims to accelerate the enterprise use of Agile methodologies in a consistent and ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... ... are now treating sleep apnea using cutting-edge Oventus O2Vent technology. As ... serious sleep disorder characterized by frequent cessation in breathing. Oral appliances can offer ...
(Date:10/12/2017)... ... October 12, 2017 , ... The American College of Medical Informatics ... PhD, FACMI, during the Opening Session of AMIA’s Annual Symposium in Washington, D.C. AMIA’s ... of Morris F. Collen, a pioneer in the field of medical informatics, this prestigious ...
(Date:10/12/2017)... ... October 12, 2017 , ... HMP , a leader in ... 2017 Folio Magazine Eddie Digital Award for ‘Best B-to-B Healthcare Website.’ Winners were announced ... 2017. , The annual award competition recognizes editorial and design excellence across a range ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... ... (HLA), the nation's first interactive health literacy software tool, and the Cancer Patient ... aspects of cancer patient education, today announce a new strategic alliance. , ...
Breaking Medicine News(10 mins):
(Date:10/5/2017)... Ill. , Oct. 5, 2017  In ... Association of Oral and Maxillofacial Surgeons (AAOMS) released ... opioids – to be used as a first-line ... pain. Recognizing ... the AAOMS White Paper "Opioid Prescribing: Acute and ...
(Date:10/2/2017)... Mich. , Oct. 2, 2017 Diplomat ... 8th Day Software and Consulting, LLC , and ... 8th Day Software, based in Tennessee ... LLC. 8th Day expands EnvoyHealth,s service offerings for health ... development. "In an ...
(Date:10/2/2017)... 2, 2017 The Rebound mobile app is poised ... reverse the tide of prescription drug addiction. The app empowers ... intake and stepping down their dosage in a safe, controlled ... December 2017; the first 100,000 people to sign up will ... ...
Breaking Medicine Technology: